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Summory
From the saliva of the vampire bar Desmodus rotundus, we isolated
an unknown anticoagulant protein which we have named draculin.
Its molecular mass as determined by non-reduced SDS-PAGE is about
83 kDa The reduced polypeptide shows a slower migration. HPLC in
a molecular sieve matrix yields a single, symmetrical peak comespond-
ing to 88.5 kDa. Isoelectric focusing shows an acidic protein with
pl = 4.14.2. Aminoacid analysis is compatible with a singie chain
polypeptide of about 80 kDa. Cyanogen bromide cieavage yields a
single 16-aminoacid peptide, conesponding to the amino-terminus of
the native molecule. Draculin inhibits the activated form of coagulation
factors IX and X It does not act on thrombin, trypsin, chymotrypsin and
does not express fibrinolytic activity. The inhibition is immediate and
not readily reversible, with a stoichiometry of about wo molecules of
draculin per molecule of factor IXa or Xa. Surprisingly, the inhibitory
activity against either factor is not affected by the presence of the other.
Draculin binds quantitatively to either immobilised factor Xa or factor
IXa. Our preliminary interpretation is that there are two forms of
draculin that hardly differ in structure. Both bind to factor Xa and to
factor IXa but one form inhibits factor Xa and the other inhibits factor
IXa.
When added to plasma, draculin increases the lag phase as well as
the height of the peak of thrombin generation.
lnlroduclion
The anticoagulant propefiies of vampire bat saliva have been intui-
tively known for many years as is witnessed by their name. Vampir,
since the early middle ages or even before indicated blood drinking
"semi-dead" in eastern European folk1ore. The name evidently has
been extended to haematophagous bats after these have become known
to Europeans, i. e. after 1492. One of the first documented accounts on
the anticoagulant effect of saliva from an haematophagous batwas
done in 1932by Bier, and some years later by Romana (1,2). After
these, very few papers have appeared on this subject. At present, he
best characterized factor from vampire bat saliva is a recently isolated
plasminogen activator from extracts of vampire salivary glands (3). It is
not clear if this comesponds to the plasminogen activator from vampire
bat saliva previously described by Hawkey (4) and Cartwdght (5).
Conespondence to:Dr. H. C Hemker, Department of Biochemistry, Medi-
cal Faculty, University of Maastricht, P O Box 616, N-6200MD, Maastricht,
The Netherlands - FAX Number: +3 1 43 670988
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Here, we report results on the isolation and partial characterization
of the anticoagulant factor present in vampire bat saliva and we deter-
mined its site of action in the coagulation mechanism. We have purified
the anticoagulant factor to apparent homogeneity and show that it is an
acidic (pI = 4.15) 88.5 kDa glycoprotein which interacts with purified
factor IXa and Xa and inhibits thrombin generation in human plasma.
Moleriols ond Melhods
Sephacryl S-200 (Pharmacia, Sweden), hydroxyapatite (BioGel HTP), Affi-
Gel-15, and acrylamide (BioRad Labs), Activated Thrombofax, and rabbit
brain partial Thromboplastin (Ortho Diagnostic Systems, Raritan, NJ, USA)
were obtained from commercial sources. Coagulation factors were purified
by established procedures by Dr. Rob Wagenvoord (Dept. of Biochemistry,
Univ of Limburg, Maastricht, The Netherlands). Chromogenic substrates were
obtained from Kabi (Sweden) Thiobenzyl Benzyloxicarbonyl-L-lysinate ' HCI
and p'-nitrophenyl-p-guanidobenzoate . HCI were from Sigma All other
reagents used were also of the highest quality available. The buffers used were
A: 0.05 M Tris-HCl, 0 I M NaCl pH 7.35, with 0.5% of egg albumin (Sigma)
and B: Buffer A atpHT 9 with 20 mM EDTA.
Animals
Vampire bats (Devnodus rotundrs,) were regularly captured from wild colo-
nies living in a cave in the northwest part of Venezuela (State of Falc6n) in a
region where rabies is reportedly absent. Twenty vampires were curently kept
in captivity, in individual cages of the metabolic type (Acme Metal Products,
Chicago, IL, USA), under controlled light and temperature (25o C). The animals
were maintained on bovine blood anticoagulated with 3.2% sodium citrate at
a ratio of I : 9, Food was given every 24 h, always in the late afternoon. Water
was given ad libitum (6).
Saliva Collection
For saliva collection, the vampires were anaesthetized with a mixture of
2.5V0 2-bromo-2-chloro, 1,1,1-trifluorethane (Halothan, Hoechst), 30% nitrous
oxide, in oxygen (5, 6). Once anaesthetized, 20pl of 1% pilocarpine (Isopto
Carpin, Alcon Labs., Inc, Ft Worth, TX, USA) was placed in the mouth in
order to stimulate salivation. It was observed that incidentally wounding of the
gingivae with the plastic pipette tip that was used to apply the pilocarpine
caused a very minor bleeding that stopped almost immediately. Saliva was
collected in plastic microcentrifuge tubes, placed in ice. The saliva collection
took 30 to 40 min, with a regular yield of about 0.5 ml/animal. Individual
samples were kept at -30o C until use.
lsolation of the Anticoagulant Factor from Vampire Bat Saliva
The protocol routinely used was as follows: Saliva (=5 ml, 15 mg of
protein) was thawed and dialysed for six hours against 10 litres of distilled
water The dialysate was centrifuged at 48,000 X g during 20 min and the clear
supematant was lyophilized and redissolved in 1.5 ml of distilled water This
was loaded on a Sephacryl 5-200 column (2 5 x 30 cm) and eluted with dis-
tilled water at a rate of 0 5 ml/min at room temperature Fractions of 2 ml
were collected and the relative protein concentration as well as the anti-Xa
activity were measured every two fractions Anti-Xa activity of the fractions
was assayed using a micro-plate adaptation of the FXa assay based on the
hydrolysis of the chromogenic substrate 5-2222 as follows: Each microplate
well contained 6 25 nM FXa, 50 mM Tris pH 7.35 and an aliquot of the
fractions, in a total volume of I 50 pl Reaction was started with 20 pl of 4 mM
3-2222 and after 10 min of incubation at 37" C the absorbency at405 nm was
recorded in a micro-plate reader (Bio-Tek, Model EL312e). Fractions with
anti-Xa activity were pooled and lyophilized The lyophilized material was
dissolved in 1 mM NaCl (3-5 ml) and the pH adjusted to 7 2 with NaOH. The
sample was loaded on a hydroxyapatite column (1 X 7 5 cm, Biogel HTP)
equilibrated with 1 mM NaCl, pH 7 .2 After all of the sample was loaded, the
columi was washed with 6 column volumes of 1 mM NaCl (pH 7 2) fbl-
lowed by 2 column volumes of 200 mM potassium phosphate, pH 6 8 At
this point, a phosphate gradient from 200 mM to 1 M (otal volume = 30 ml)
was initiated One ml fractions were collected at a rate of 0.3 ml/min. The
anti-Xa activity appeared at about 0 3 M phosphate, while most of the protein
eluted with the initial washing and the 200 mM phosphate The active fractions
were pooled and concentrated by ultrafiltration through an Amicon XM-50
filter.
A high degree of purification can also be obtained after cluomatography of
crude saliva (dialysed against 1 mM NaCl) on hydroxyapatite, with omisson of
the Sephacryl step. Draculin obtained by this single step procedure is always
slightly contaminated by a lower molecular weight polypeptide which elutes
from the hydroxyapatite column at the same phosphate concentration as dracu-
lin.
Coagulation Assays
a) Human whole blood coagulation time (WBCT) was measured in one
ml samples collected after discarding the first 2 ml of blood Coagulation
was allowed to proceed at3'7'C, in glass tubes containing 50 pl of EACA
(114 mg/ml).
l) Activated partial thromboplastin tune (aPTT) was measured using a
commercial partial Thromboplastin (Activated Thrombofax, Ortho Diagnostic
Systems, Raritan, NJ, USA), which contains Elagic acid as activator
c) Prothrombin time (PT) was measured using a commercial Brain Throm-
boplastin/calcium chloride reagent (Ortho)
d) Thrombin time (TT) was determined with bovine thrombin (Sigma
Chem, St Louis, MO, USA) Experimental conditions were chosen in order to
obtain a TT of 30 seconds for the control.
Al1 coagulation times were read manually by tilting the tubes.
Factor Xa Activity
Factor Xa was assayed by its activity on the chromogenic substrate 5-2337
(Kabi Diagnostica, Sweden). Usually 10 pl samples were put in 0.490 ml of
buffer B containing 4 mM of the substrate. The reaction was followed at 37" C,
at 405 nm in a home made fixed dual-wavelength p otometer (Biochemistry
and Instrumental Dept., Univ of Limburg), and all relevant parameters were
calculated by a dedicated software developed for that instrument (Laudy, P.,
Instrumental Department, Univ. of Limburg) Factor Xa concentration was
determined by titration with p'-N-p-guanidobenzoate as described by Jameson
et al. (7).
Factor IXa Activity
Factor IXa was assayed according to the principles worked out by van
Dieyen et al (8) as further elaborated by Wagenvoord et al. (9) We measured
the enzymatic activity on factor X activation in a system where the non-factor
IXa components of the tenase complex are present in excess: factorVllla
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Flg.1 Protein and anti-FXa activity profile from fractions obtained after
molecular sieve of lyophilised vampire bat saliva through sephacryl S-200 Co-
lumn size was 2.5 X 30 cm; equilibration and elution was done with delonized
water and 2 ml fractions were collected Dashed line comesponds to the inhibi-
tory activity assayed with the microplate system described in Methods and
expressed as the decrease of absorbency measured at 405 nm Solid line cor-
responds to the relative protein concentration determined by Bradford's method
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Flg 2 Antr-FXa activity profile of material eluted from a hydroxyapatite
column. Column (1 X 7 5 cm) was loaded with active material obtained from
Sephacryl S-200. Fractions volume was I 0 ml. Inhibitory activity expressed as
in Fig. 1 See Methods ection for details
(10 nM), phospholipid (PS,PC 20/80, I pM), and Ca++ (5 mM). The samples
contained up to I nM of factor IXa mixed with up to 2 nM draculin. Factor IXa
and draculin were incubated for at least one minute before the other compo-
nents of tenase were added, except for the experiment of Fig 7 The reaction
was initiated by addition of purified factorx (200 nM) The production of
factor Xa was followed on subsamples taken into EDTA buffer, containing the
chromogenic substrate 5-2337, as described above. Typically 1 nM of factor
IXa will cause a reaction velocity of 200 nM qf factor Xa being lbrmed per
minute in this system Because never more than 2 nM of draculin was added per
nM of factor IXa, the inihibitory action of draculin on factor Xa would not
significantly interfere with the outcome of the factor IXa determination
Additionally, FIXa amidolytic activity was tested on thiobenzyl benzylocar-
bonyl-LJysinate as described by Green and Shaw (l 0)
Determination of Other Proteases
The following proteases were tested on the chromogenic substrates indi-
cated: thrombin-S2238; trpysin-S2160; chymotrypsin-S2586; plasmin-S2160;
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fig.3 SDS-Polyacrylamide g l electrophoresis of draculin. Lane 1: crude
saliva; lane 2: non-reduced draculin (10 pg), lane 3: reduced raculin (10 pg);
Lane 4 conesponds to the low molecular weight markers from Pharmacia.
Protein stainine with Coomassie Blue
plasma kallikein-S2302. Their activity was tested in the presence and in the
absence of roughly equimolar as well as up to tenfold excess amounts of dracu-
lin.
Protein determination was done using the method described by Bradford
( 1 1 ) .
SDS-Polyacrylamide gelelectrophoresis was done as described by Shagger
and von Jagow (12). Periodic acid-Schiff staining for giycoproteins was done
as described (13).
Isoelectric focusing was performed on aSarose in a Multiphor LKB
(Sweden) electrophoresis chamber as described by Vesterberg and Gramstrup-
Christensen (14), with minor modifications. Ampholine (pH 3 5-10, LKB,
Sweden) was added to obtain a final concentratton f 5Vo.
HPLC of purified draculin was performed in a Shimadzu HPLC equipment
(Shrmadzu Corp., Japan) using a silica based molecular sieve column (10 pm
Protein Pak 300 sw,Waters, Millipore Cory., USA). Equilibration of the co-
lumn and elution of the sample was done with 250 mM potassium phosphate,
pH 6.8. Calibration of this column was done with molecular weight markers
from Pharmacia (Sweden).
Immobilization of FIXa and FXa on AffiGel-L5 was done as indicated in the
manufacturer brochure, using 1.2 mg of each purified factor for coupling to
0 5 ml of gel (bed volume).
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Effect of Immobilized FlXa or FXa on the Activity of Draculin
Draculin was incubated for two minutes with 150 pl of inactivated AffiGel-
15 (control) and after centrifugation for one minute at 12,000 X g an aliquot
of the supernatant was assayed for inhibition of FIXa or FXa in the standard
assay The amount of draculin was chosen to obtain 95-100% inhibition of the
enzymatic activity of the coresponding factors. Identical amounts of draculin
were incubated with a) FXa-AffiGel, or b) FIXa-AffiGel and similarly tested
Thrombin generation experiments (TGT) were executed as previously
described (15).
Aminoacid Composition and Partial Aminoacid Sequence
Draculin was further purified, prior to protein chemistry, by reverse phase
HPLC on a C- 1 8 column (Vydac 201 TP, The Separations Group, Hesperia CA,
or Asahipak ODP-50, from Anspec Co., Ann Arbor, MI) equilibrated in 0.1%
trifluoroacetic acid and developed with a gradient (0.87o per minute) of aceto-
nitrile. Each column yielded a single peak. Amino acid composition was deter-
mined by derivatisation with phenyl isothiocyanate (PITC) after vapour phase
acid hydrolysis for 16h at 110" C ("Picotag" methodology, Milligen Corp,
Waters Division).
Resulls ond Discussion
The anticoagulant factor present in vampire bat saliva was pudfied
to homogeneity as described in the Methods ection. Fig. 1 shows the
protein separation patterrl and anti-Xa activity obtained after molecular
sieve of dialysed, lyophilized saliva, through Sephacryl 5-200. Fig.2
shows results of the chromatography of the pooled, active fractions, on
a column of hydroxyapatite as described in Methods. Most of the
protein comes through with the washing (1 mM NaCl) and 0.2 M phos-
phate (pattern not shown in the figure), while anti-Xa activity only
appeaN after establishment of the gradient from 0.2 M to 1.0 M phos-
phate, at about 0.3 M phosphate.
SDS-polyacrylamide g l electrophoresis of the active material
eluted from the hydroxyapatite column, showed a single band cone-
sponding to a molecular mass in the range of 80 to 85 kDa. Under re-
ducing conditions, this band migrates as an apparently slightly higher
molecular mass component, suggesting the presence of intra-chain
disulphide bonds (Fig. 3, lanes 2 and 3). The protein band gives a strong
positive reaction for carbohydrates with the periodic acid-Schiff stain
(not shown).
HPLC of the purified native draculin showed a singie, symmetrical
protein peak eluting at a position coffesponding toa molecular mass of
88.5 kDa (Fig. 4). This result was obtained using 0.25 M phosphate for
elution of the column. Several trials using lower ionic strength eluent
resulted in apparent binding of the protein to the column matrix, which
markedly retarded elution of the protein. Fig. 5 shows that isolelectric
focusing of draculin in an agarose based gel resulted in a single poly-
peptide band which immobilizes at pI = 4.14.2.
The amino acid composition of non-reduced (native) and reduced,
alkylated (S-pyridilethyl) draculin is shown in Table 1. In SPE dra-
culin, seven moles of SPE cysteine per mole of protein was also re-
covered, Form the amino acid composition a molecular weight of
approximately 80 Da can be calculated, which is in agreement with the
molecular mass obtained from SDS-PAGE. The contribution of the car-
bohydrate moiety seems to amount o about I\Vo of the polypeptide
weight, as indicated by the molecular mass obtained from HPLC mole-
cular sieve of native draculin (88.5 kDa). Cleavage of draculin with
cyanogen bromide yields a single peptide with apparent molecular
weight around 7000 Da, with the sequence NH2-ARRRGVRWCTISK-
PEA. This sequence contains the 16-aminoacid sequence from intact
draculin, indicating that it represents he amino-terminus of the mole-
cule.
Preliminary experiments on the effect of draculin on blood coagula-
tion indicated that draculin prolonged the coagulation time of whole
human blood (WBCT), as well as the prothrombin time (PT, extrinsic
pathway) or the activated partial thromboplastin time (aPTT, instrinsic
pathway) of citrated human plasma. About 50 nM final concentration
of draculin doubled the aPTT and the WBCT. The same concentration
prolonged the PT from 14 (control) to 18 s. Under the same conditions,
draculin did not affect the thrombin time or the activity of purified
thrombin on the chromogenic substrate 5-2238. Neither did it inhibit
trypsin, chymotrypsin, plasmin or plasma kallikein. These results
suggested a relatively specific anticoagulant effect located in the co-
aguiation cascade at the level of factor X, or factor X activation. To
further define the mechanism(s) of the anticoagulant effect of draculin
we investigated its effect on the catalytic activity of purified factors.
Fig. 6 shows the progress of the hydrolysis of the chromogenic sub-
strate S-2337 by factorXa, expressed as the change in absorbency at
405 nm. Addition of draculin to the system results in an immediate
inhibition of the catalytic activity of the enzyme. iuggesting avery fast
interaction between factor Xa and draculin. We repeated this experi-
ment at a series of factor Xa and draculin concentrations but inhibition
always was apparently complete within the 5-10 s that are required for
addition and mixing of draculin in the solution No stopped flow ex-
periments could be canied out in our laboratories. To our surprise
draculin also inlibits the activation of factor X catalysed by factor IXa.
If 0.3,0.5 or 1.0nM of factorlXa is incubated with an equimolar or
excess amount of draculin, then, after addition of the other components
of the tenase system in excess, i.e. factorVllla (10 or 20nM) and
phospholipid (2 or 20 pM), no factor X converting activity is observed.
This is illustrated in Fig. 7. This figure also shows that the order of ad-
dition of the reaction components influences the velocity of inhibition.
This means that factor IXa in the tenase complex system is to a certain
degree protected from draculin action and that fast inhibition is only
achieved when free factor IXa interacts with draculin. This sussests
Table I Amino acid composition of non-reduced (native) and reduced,
alkylated (s-pyridylethyl, SPE) draculin
Amino acid Native
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Fig.4 HPLC of purified draculin. A Protein Pak 300sw column (7 8 x 300
mm), was equilibrated and eluted with 250 mM potassium phosphate, pH 6 8
Figures (kDa) conespond to molecular weight markers from Pharmacia used
for column calibration (n = 5, t SEM). No difference in retention time of the
markers was observed with Tris or HEPES buffers The insert conesponds to
a typical run of 10 pg of draculin (S = start, E = end of the run)
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Flg.5 Isoelectric focusing of purified draculin. Fifteen pr"g of protein was
applied. Insert shows the actual agarose gel after staining with Coomassie Blue
(0 indicates original position of the sample) Isolelectric point markers used
were: 1, Trypsinogen (93); 2, Lentil Lectin (8.15); 3, Horse myoglobin (6.85);
4, BJactoglobulin A (5.2); 5, Soybean trypsin inhibitor (a.55); 6, Amylogluco-
sidase (3.5)
that the inhibition observed isbasically due to the effect of draculin on
free factor IXa. Comparable protection of the amidolytic activity of
factor Xa on 5-2337 is observed when the components of the pro-
thrombinase system (factor Va and phospholipids) are added (results
not shown).
The dose-response for the interaction between sub-equimolar
amounts of draculin and factor IXa or Xa is depicted in Fig. 8. As can
be seen, the inhibitory effect is dose-dependent a d shows a tendency
towards complete inhibition when about wo moles of draculin (MW =
88.5 kDa) are added to one mole of either factor. A similar conclusion
can be drawn from the results shown in the insert, which describe the
effect of draculin on the activity of factor IXa on the chromogenic sub-
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Flg. 6 Inhibition of factor Xa amidolytic activity by draculin. Progress curve
for the hydrolysis ofthe chromogenic substrate S-2337 by purified coagulation
factor Xa (25 nM), expressed as the change inabsorbency at 405 nm After 22
seconds, buffer (Control) or draculin (50 nM) was added and the reaction was
allowed to proceed for another 30 s
strate Thiobenzyl Benzyloxycarbonyl-L-lysinate (Z-Lys-SB21 . HCI).
Since this is not a good substrate for factor IXa, relatively high con-
centrations of enzyme must be used in order to have a reasonable rate
to hydrolysis. Due to this handicap, only two molecular ratios 0f dra-
culin:factor IXa were examined, however, their inhibitory effect
clearly falls within the expocted range assuming a molar ratio of 2:1
and a mo1ecu1ar mass for draculin of 88.5 kDa (dashed line). This
inhibition of the activity of FIXa on an artificial substrate confirms that
the inhibitory activity 0f draculin observed in the tenase system is
indeed ue to a direct effect of draculin on factor IXa.
Results from dose-response experiments done with six batches of
purified draculin, show a variability in the stoichiometry that ranges
between L8 and 2.l This variability could be related to a variable
degree of microheterogeneity, e. g. caused by different degrees of gly-
cosylation, ofnative draculin At present we do not have experimental
evidence on the possible dependence of the biological activity of
draculin and the level of glycosylation.
Table 2 shows that the effect of draculin is specific for the activated
form of factor X. As can be seen, the inhibitory effect of draculin on the
activity of FXa is not affected by the presence of FX or a chemically
modified FXa (Dansyl-Glu-Gly-Arg-chloromethyl ketone-FXa) which
is catalytically inactive, Table 2 also shows a suryrising lack of com-
petition between FIXa and FXa in their interaction with draculin. Incu-
bation of draculin with an excess of FIXa does not affect he inhibition
of FXa by draculin. Table 3 indicates that interaction of draculin with
either factor IXa or Xa which have been immobilized to a matrix
(AffiGel-15), aiso immobilizes the inhibitory activity of the protein
against he other factor. We attribute the weak residual inhibition
observed after incubation with FIXa-AffiGel to a less than optimal
coupling of this factor to the matrix.
At the moment we cannot propose a detailed mechanism of action
of draculin 0n factor Xa and/or factor IXa. From its size one might
think draculin to be related to one of the many known serpins but the
N{erminal amino acid sequence does not show homology with this
group of proteins. Also the inhibition is much faster than that obtained
with most serpins. Compared to the typical anticoagulant serpin anti-
thrombin we see that the specificity is higher (no inhibition of throm-
bin) and the action is much faster [the pseudo first order decay constant
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of thrombin-antithrombin interaction being 1.49min-t/pM, which
accounts for a halflife time of thrombin of over 25 s in a 1 Lr,M solution
of antithrombin (16), the interaction of antithrombin with other
activated clotting factors is even considerably slower]. Furthermore the
completely unexpected observation that factor Xa- and factor IXa
inhibition are not mutually exclusive is, to out knowledge, not found
with any of the known serpins.
This latter fact is for the moment he most difficult to explain. One
has to reconcile the following four observations: a) apparent homo-
geneity of our preparation by the usual criteria, inclusive a single
aminoterminal sequence, b) a 2:1 binding stoichiometry of factor Xa
or IXa inhibition that is variable between 1.8 and2.7. c) lack of com-
0 3 0 6 0 9 0
Time (sec)
Fig 7 Effecl of draculin on factor X activation by factor IXa. The complete
tenase system was used, as described in Methods This figure also shows the
effect of varying the order of addition of draculin (DRAC) to the reaction
system
I Control without draculin; + sequence of addition: factor IXa, phospholipids,
factor VIIIa, draculin; ! sequence of addition: factor IXa, phospholipids,
draculin, factor VIIIa A Sequence of addition: factor IXa, draculin, phospho-
lipids, factor VIIIa. The substrate of the reaction, i e. factor X, was always
added last to start he reaction
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Fig 8 Stoichiometry of draculin-clotting factor interaction. Stoichiometry
of the inhibition of purified factor IXa (circles) and purified factor Xa (squares)
by draculin (standard assay) Insert shows results obtained for the effect of dra-
culin on purified factor IXa using Z-Lys-SBzl . HCI as substrate (filled circles)
The dashed line coresponds to the theoretical inhibition that will be obtained
assuming a 2: I stoichiometry
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Fig 9 Effect of draculin on intrinsic thrombin generatron i  human, defi-
brinated plasma Experimental protocol and analysis of the data, as described in
Methods and Ref. 13. Open cilcles, control; closed circles, 1 8 nM draculin
Table 2 Effect of the addition of FX, modified FXa and FIXa on the anti-Xa
activity of draculin
Addition* FXa activity (mA/min)
shown in Fig. 9. As can be seen, thrombin generation is both retarded
and inhibited by draculin. The increase of the lag phase is brought
about by factor Xa inhibition, while the decrease of the peak value is
due to factor IX inhibition (17).
To summarize, in this paper we report he isolation from vampire bat
saliva of a new anticoagulant glycoprotein with a molecular mass of
88 5 kDa and isoelectric point of 4.14.2.I1 appears as a single chain
polypeptide. However, from the functional and binding studies we
have to accept the possibility of a microheterogeneity. This polypep-
tide, which we named draculin, seems [o be highly specific for the
activated forms of coagulation factors IX and X and its inhibitory
effect is immediate The stoichiometry (2: l) of inhibition and the inter-
action with immobilised activated factor Xa and IXa as well as the lack
of competition between FIXa and FXa for draculin, suggests the
existence of two specific inhibrtory sites, possibly present in two
hardly different polypeptide chains.
Draculin is different from other anti-Xa molecules that have been re-
cently isolated from other animal sources, uch as Antistasin (18), TAP
(19), the anti-FXa isolated from black fly salivary glands (20) and
anticoagulants from leeches (21) All of them are polypeptides with
molecular weights below 20 kDa and their effect rs characterized by a
slow onset that requires from l0 to l5 min of preincubation for maxi-
mal inhibition. AntilX activity has been observed in crude extracts
from the tick Ornithodorus moubata, however, it is not clear if the
effect of the anticoagulant is on FIX or FIXa (22). Draculin is also
different from Ecotin the serine protease inhibitor isolated homE. coli
(23).
To our knowledge, draculin is the first natural polypeptide for which
immediate anti-Ixa and anti-Xa activities have been described. The
discovery of this new anticoagulant provides anew tool for studies of
the coagulation mechanism(s), and the possibility of design of sub-
strates for the assay of factor IXa. Further, it opens a new approach to
the strategy in the search for new anticoagulants with therapeutic po-
tential. The observation that vampires are immune to the anticoagulant
action of their own saliva suggests hat there are interesting differences
between the clotting system of these mammals and others, that remain
to be investigated.
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